Nussbaum Ran (CIK 1609805) reported 7 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2025-10-17). Recent activity: Sell KROS (2.3M shares), Sell KROS (1.1M shares), Sell KROS (1.2M shares), Sell KROS (155,262 shares), Buy LBRX (411,681 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-17 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 2.3M | $40.6M |
| 2025-10-17 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 1.1M | $19.9M |
| 2025-10-17 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 1.2M | $21.8M |
| 2025-10-17 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 155,262 | $2.8M |
| 2025-09-16 | LB PHARMACEUTICALS INC (LBRX) | Director | Buy | 411,681 | $0 |
| 2025-09-16 | LB PHARMACEUTICALS INC (LBRX) | Director | Buy | 1.0M | $15.0M |
| 2025-06-06 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 5,250 | $0 |
Source: SEC Form 4 filings · as of 2025-10-17